Zincofax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zincofax

Quick Facts

Property Description
Active ingredient Zinc Oxide [INN]
Form Ointment, Paste, or Cream
Pharmacological class Topical Skin Protectant, Astringent
Common use Prevention and management of skin irritation
Origin Synthetic (for the compound Zinc Oxide)

What Type of Medicine is Zincofax and How is it Classified?

Zincofax is an established Over-the-Counter (OTC) topical preparation that is officially categorized as a Topical Skin Protectant and mild Astringent. Its identity is founded upon its sole active medicinal component, Zinc Oxide [INN], an inorganic compound that works exclusively via surface action without systemic absorption. Zinc Oxide preparations are recognized for their use in protecting injured or exposed skin from harmful or irritating stimuli. The brand is particularly well-established in the Canadian market, frequently cited for its use in pediatric care settings. This classification strictly distinguishes it as a surface-acting treatment, unlike systemic medications that require internal physiological engagement.

Composition and Form: What is Zincofax Made Of?

Zincofax is typically formulated as a dense, viscous Ointment, Paste, or Cream, which acts as the vehicle for the Zinc Oxide. This dosage form relies heavily on a lipophilic hydrocarbon base, such as high concentrations of White Petrolatum, which provides its characteristic water-repellent properties. The high viscosity of such petrolatum-based formulations is clinically recognized for establishing a durable occlusive barrier on the skin. The composition is defined by its single-ingredient medicinal focus, with the base chosen to maximize the adherence and durability of the protective layer when applied topically.

General Therapeutic Purpose: What is the Main Benefit of Zincofax?

The main purpose of Zincofax is to prevent and manage superficial skin irritation and wetness by establishing a resilient protective barrier on the skin's surface. A typical use scenario involves applying the ointment to skin areas prone to consistent moisture exposure. This primary therapeutic benefit stems directly from the base's ability to repel moisture and the mild Astringent effect of Zinc Oxide. By creating this sustained physical shield against external irritants and friction, the preparation provides a stable, non-systemic environment that supports the natural recovery process of irritated skin.

Regulatory References

  1. Zinc oxide overdose (MedlinePlus)

What side effects are possible with Zincofax?

Possible Side Effects and Safety Information

The following safety information for Zincofax, which contains Zinc Oxide, is derived exclusively from official government regulatory sources, such as the U.S. National Library of Medicine (NIH) and Health Canada monographs. As a non-systemic, topical skin protectant, its documented adverse reactions are primarily localized.


Documented Adverse Reactions

Adverse effects listed in regulatory documents are generally restricted to the site of application and relate to the Skin and Subcutaneous Tissue Disorders (Dermatological SOC).

Adverse Reaction Category Examples Listed in Official Documents
Local Skin Reactions Skin irritation, rash, hives, or itching at the application site.
Frequency Classification Incidence of these reactions is typically listed as Not Known or Rare in official monographs.

Serious Safety Considerations and Restrictions

While rare for topical Zinc Oxide, the potential for a severe allergic reaction is documented as a necessary safety warning in regulatory labeling. Signs of such a reaction include severe dizziness, difficulty breathing, or swelling of the face, throat, or tongue.

Safety Restrictions

  • Contraindication: The product is formally contraindicated for use in individuals with a known hypersensitivity or allergy to Zinc Oxide or any other component of the formulation.
  • Application Site: The official label advises against applying the ointment to broken or damaged skin without professional consultation.
  • Exposure Warning: The product should be strictly kept out of the eyes.

Population Safety Statements

Due to the product’s non-systemic nature, specific warnings related to organ impairment (e.g., liver or kidney function) are generally absent from official labeling. For use in children under 6 months or during pregnancy or lactation, regulatory sources advise consulting a healthcare professional.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for topical Zinc Oxide preparations, such as Zincofax, defines the overdose risk strictly around accidental oral ingestion, as the active ingredient is not systematically absorbed when used topically. Overdose is classified by regulators as unlikely when the product is used as directed.

The primary documented manifestations following ingestion are localized to the gastrointestinal system. These include a specific cluster of symptoms: nausea, vomiting, stomach pain (colic), and diarrhea. Despite the product generally being classified as not very poisonous if ingested, immediate regulatory action is mandated if the preparation is swallowed. You must contact a Poison Control Center right away or seek emergency medical attention.

The management protocol for overdose is defined as symptomatic and supportive, confirming that no specific antidote is available. In a clinical setting, treatment focuses on supportive care and may include the continuous monitoring of vital signs. Other procedural steps explicitly described in regulatory documentation for managing ingestion may include the administration of intravenous fluids, activated charcoal, and diagnostic assessments such as blood tests or an ECG.

Therapeutic Uses of Zincofax

What Zincofax Treats: Main Uses and Benefits

The primary therapeutic focus for Zincofax is applied across domains where additional symptomatic support is needed related to skin protection. The active ingredient Zinc Oxide is used to help treat and prevent diaper rash and protect chafed skin.

It is commonly used to address the characteristic cluster of redness, soreness, and mild irritation that defines diaper dermatitis in infants, and it is also relevant for managing symptoms of chafing and chapping caused by friction or environmental factors like windburn. This preparation is applied in scenarios marked by prolonged wetness, including supportive care for adults experiencing symptoms of incontinence-associated dermatitis. The preparation helps address symptom clusters that may become intense or disruptive due to wetness, and supports the patient's natural recovery process while providing support that helps ease the overall symptom burden.


Summary of Therapeutic Focus: Relief for Surface Irritation and Wetness-Related Discomfort

Indication Category Symptoms Addressed Patient Benefit
Pediatric Use Redness, soreness, mild irritation Supports comfort during symptomatic periods
Topical Protection Chafing, windburn, minor abrasions assists with maintaining functional stability
Adult Care Rashes associated with prolonged wetness Helps patients cope more steadily with symptom fluctuations

Regulatory References

  1. NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Who can and cannot use Zincofax?

This section outlines the official population-eligibility rules for Zincofax, based strictly on the labeling for its active ingredient, Zinc Oxide, an Over-the-Counter (OTC) Topical Skin Protectant. Eligibility constraints are primarily related to individual hypersensitivity and the condition of the application site.


Approved and Labeled Populations

Zinc Oxide topical preparations are generally permitted for use across all age groups (Infants, Children, Adolescents, and Adults) for its established indications. Use is explicitly documented and established for the pediatric population for the prevention and treatment of diaper rash.


Contraindications and Restrictions

Condition Status Detail
Hypersensitivity Contraindicated Use is forbidden for patients with a known allergy or hypersensitivity to Zinc Oxide or any other component in the formulation.
Wounds/Burns Restricted Avoid application on deep puncture wounds, animal bites, or serious burns, as stated in regulatory warnings.
Skin Infection Conditional Consult a health professional if the skin condition includes signs of infection or does not improve within seven days.
Pregnancy/Lactation Precautionary Patients who are pregnant or breastfeeding should consult a health professional before use.

Due to the negligible systemic absorption of this topical product, official labeling does not include restrictions based on major systemic comorbidities such as hepatic or renal impairment.

What should I know about interactions with other medicines?

The interaction profile for Zincofax is characterized by its classification as a topical protectant with minimal to negligible systemic absorption of its active ingredient, Zinc Oxide, as documented in regulatory information. This non-systemic mechanism of action eliminates the possibility of most common systemic drug-drug interactions.

Interaction Scope

Type of Interaction Official Regulatory Status
Pharmacokinetic (PK) Interactions None documented in official labels (e.g., CYP-enzyme, transporter effects) due to lack of systemic absorption.
Pharmacodynamic (PD) Interactions None documented with systemic medicines (e.g., additive effects).
Food, Alcohol, or Herbal Interactions None documented in regulatory prescribing information for the topical application route.

Interaction-Related Restrictions

The only official constraint noted in pharmaceutical formularies is a documented chemical incompatibility between the substance Zinc Oxide and the systemic medicinal product, Benzylpenicillin. This is classified as a physical or chemical restriction, meaning the compounds should not be combined. Regulatory documents do not specify mandatory time-separation rules for co-administering Zincofax with other topical creams, though physical interference with other surface-acting medicines is the only plausible interaction type given the product's occlusive, surface-level action. The overall structure of the regulatory profile confirms that interaction concerns are limited to this specific incompatibility.

Mechanism of Action

The action of this topical preparation involves a localized dual mechanism, combining the biophysical barrier formation of the formulation with the local chemical action of the active ingredient, Zinc Oxide. This process is confined to the skin's surface with negligible systemic engagement.

️ Creating a Biophysical Occlusive Barrier

This domain focuses on the physical interaction of the highly viscous ointment base with the stratum corneum, resulting in a dense film. The base forms a dense, water-repellent film that mediates a physical separation between the external environment and the underlying tissue. This occlusion modulates the skin's surface microenvironment by limiting the mechanical action of friction.

Local Modulation of Inflammation and Tissue Repair

This mechanistic domain is driven by the zinc ions (Zn^2+) released at the skin surface, which engage a set of chemical and cellular pathways. These ions exert an astringent action by precipitating superficial proteins, which mediates the reduction of surface exudate and tissue consolidation. Furthermore, Zn^2+ locally modulates the inflammatory cascade through the reduction of pro-inflammatory cytokine release and functions as a cofactor essential for keratinocyte proliferation.

Dosage and Administration Information

How to Use Zincofax: Official Administration Guidelines

Zincofax is a topical preparation containing Zinc Oxide that must be administered strictly to the skin surface to form a protective barrier. The usage protocol is designed around creating and maintaining this physical shield against external irritants.


Administration Scope

Feature Official Guideline
Route of administration Topical (Dermal application).
Dosing schedule Apply the preparation liberally to cover the affected skin area.
Preparation requirements The area must be cleansed and allowed to dry before the preparation is applied.
Age-group administration The application regimen is uniform for all user populations (infants, children, adults) requiring topical skin protection.

Usage Patterns and Frequency

Classification Description
Frequency pattern As-needed (symptom-driven) or Continuous (preventative exposure-driven).
Use-context constraints Applied as often as necessary, specifically with each diaper change and at times of prolonged wetness exposure, such as bedtime.

Procedural Structure

The established procedural steps must be followed prior to the liberal application of the product:

  • Step 1: Change wet and soiled diapers promptly, if applicable to the scenario.
  • Step 2: Cleanse the skin area thoroughly.
  • Step 3: Allow the skin to fully dry.
  • Step 4: Apply the preparation liberally.

These instructions define the use of Zincofax as a strictly topical procedure that requires specific pre-application steps to ensure the adherence of the protective layer. The regimen is structured to be flexible, specifying use either for existing irritation or continuously to maintain protection during high-risk exposure periods.

Recent Clinical Evidence

Research evidence / Overview of studies for Zincofax

Evidence for Use in Diaper Dermatitis

Research has primarily focused on the evaluation of topical Zinc Oxide in conditions associated with irritant contact diaper dermatitis (IDD), a condition characterized by redness and soreness due to wetness. The evidence base for this indication is largely characterized by its inclusion in regulatory monographs and supporting studies, consistent with established regulatory allowance.

Studies were conducted using Randomized Controlled Trials (RCTs) and systematic reviews. The research explored how the preparation was studied for symptom change over time during periods of increased symptom activity. Researchers primarily monitored infants and neonates and some older adults with similar irritative skin conditions. The primary metrics monitored included the incidence of new rash cases, the time required to achieve symptomatic recovery, and changes in rash severity using clinical scales.

Patterns were observed in the studies related to the time course of changes in skin redness and recovery within the observed time intervals. The research provides context but not individual predictions, and the findings help contextualize how patients reported their experience during periods of heightened symptom activity. Comparative evidence is often against other active products, and follow-up durations were limited in most trials.


Evidence for Use as a Skin Protectant for Chafing and Irritation

The evidence supporting the use of Zinc Oxide as a general Topical Skin Protectant for conditions like chafing, chapping, or minor environmental irritation is based on authoritative regulatory allowance for its classification and physical property assessments.

Studies monitored outcomes reflecting daily functioning or activity level by measuring changes in skin integrity after exposure to stress. Research explored short-term symptom changes by using human skin challenge models where measures of skin barrier integrity were observed after exposure to controlled irritants in healthy adult participants.


What is Still Uncertain About the Research for Zincofax

The overall body of evidence contributes significantly to understanding symptom patterns, but several research limitation frames apply:

  • Comparative Evidence: Comparative evidence is lacking for certain study types, as many RCTs compare Zinc Oxide formulations against other active products, rather than against a neutral control.
  • Long-Term Outcomes: Long-term effects are not fully established, as follow-up durations were limited in most clinical trials.
  • Research does not determine whether an individual will respond similarly, as study results reflect group averages under the specific conditions where they were conducted.

Key Studies & References Zinc Oxide Ointment USP Label Information (DailyMed/NIH)

Frequently Asked Questions (FAQ)

Common questions about Zincofax (FAQ)


Q: Is Zincofax the same as a regular diaper rash cream?

Official classifications define this product as a Topical Skin Protectant because its sole active component is Zinc Oxide. This means it works by establishing a physical barrier on the skin's surface. While many products treat skin irritation, the official classification highlights this product's specific, non-systemic mechanism of action.


Q: How quickly should I expect to see an improvement after using Zincofax?

Studies on the active ingredient have examined the time course required for symptomatic recovery in groups of patients. However, regulatory documents do not provide specific predictions for how quickly any individual person will see improvement. The product's intended purpose is to prevent and manage irritation by forming a barrier on the skin.


Q: What is the difference between Zincofax and creams containing petroleum jelly?

According to the official product information, the primary difference is the inclusion of the active ingredient, Zinc Oxide. While a plain petroleum jelly acts solely as an occlusive barrier, the Zinc Oxide component adds a mild astringent action, which supports the skin's consolidation process.


Q: Can Zincofax interact negatively with topical antibiotic ointments?

Because this is a topical, non-systemic product, regulatory documents indicate that the concerns regarding drug interactions are minimal. The only plausible type of interaction is physical interference, meaning the product's occlusive barrier may physically impact how other topical creams or ointments are absorbed or distributed.


Q: What should I do if Zincofax gets into the eyes?

Official regulatory labeling includes a warning advising that the product should be kept strictly out of the eyes. If the product does accidentally get into the eyes, the official regulatory instruction is to flush thoroughly with water.


Q: What are the inactive ingredients in Zincofax?

All inactive ingredients, also known as excipients, are required to be published in the official labeling for the formulation. This list is intended to allow users to verify the components and identify the presence of any known sensitivities.


Q: How long does the protective effect of one application of Zincofax last?

Official usage guidelines specify that the product should be applied as often as necessary, and specifically with each diaper change or other high-exposure periods. This indicates that the duration of the protective effect is highly dependent on how quickly the product is removed or degraded by external factors like moisture and friction.


Q: Do healthcare professionals routinely suggest Zincofax?

The product's usage is established in regulatory contexts, and it is frequently cited for use in pediatric care settings. Official documents confirm its place as an over-the-counter (OTC) topical skin protectant for the prevention and treatment of irritation in various user groups.


Q: What is the longest period of time Zincofax can be used continuously?

Official regulatory labeling states that the product should not be used for longer than seven consecutive days. If the condition being treated worsens or does not show improvement within this period, the label indicates that a healthcare professional should be consulted.


Q: Are there different strengths or versions of Zincofax available?

Official product databases and regulatory labeling typically list all available formulations, concentrations, and strengths marketed under the brand name. Official product entries for the brand contain information that clarifies the specific versions authorized for sale.


Q: Does Zincofax have an expiry date or shelf life after opening?

Regulatory documents mandate that all products have a specified total expiry date, which is printed on the packaging. The label notes that for stability, the product must be stored correctly and use should be avoided if the container seal is damaged or if it is past its expiration date.


Q: Does Zincofax contain any parabens or common allergens?

Because regulatory bodies require the mandatory disclosure of all inactive ingredients, users can check the official product labeling. This information allows individuals to identify whether specific compounds, such as parabens or known allergens, are present in the formulation.


Q: Have there been any official warnings or recalls related to Zincofax?

Regulatory agencies, such as the FDA and Health Canada, maintain publicly accessible databases that catalog official warnings, safety alerts, and product recalls. These resources contain the most current regulatory actions related to the product.


Q: Does sunlight affect the area where Zincofax has been applied?

The product's classification requires regulatory documents to include any warnings regarding photosensitivity or restrictions related to sun exposure. Generally, the absence of a specific warning indicates that the product's active ingredient is not known to be a photosensitizer under normal use conditions.


Q: Can Zincofax be used under clothing or a bandage?

Official labeling for this type of occlusive topical product typically includes a warning advising against tight bandaging or the use of certain types of occlusive dressings. This warning is present in the labeling unless the practice is specifically recommended by a healthcare professional.


Q: Does Zincofax have antibacterial properties?

The product is officially classified as a Topical Skin Protectant and a mild Astringent. Official labeling and claims are restricted to those properties that have been proven and approved by regulators, and generally, the product does not list antibacterial properties unless specifically included and authorized.

How should Zincofax be stored and disposed of?

How to Store and Dispose of Zincofax?

Zincofax (zinc oxide ointment) must be stored strictly according to the conditions defined in the official regulatory labeling to ensure its stability.

Storage Conditions

The product is required to be stored at Controlled Room Temperature, typically specified as 20° to 25°C (68° to 77°F), with a broader allowed range of up to 30°C in some documents. Storage conditions mandate avoiding excessive heat and humidity. The product must not be used if the container's tamper-evident seal is damaged.

Child Safety and Disposal

For safety, Zincofax must be stored in a location that is out of reach of children. If the ointment is accidentally swallowed, immediate medical help or contact with a Poison Control Center is required. Official labeling does not typically provide explicit, uniform instructions for the household disposal of unused or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zincofax found in:

A-Z Index: